|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
In all 3 cases, biopsy, histology, and immunohistochemistry using a panel of lymphoid markers (Epstein-Barr virus [EBV], CD79a, CD20, PAX-5, CD3, and CD30) resulted in the diagnosis of EBV-driven T-cell, B-cell, and Hodgkin-like LPD.
|
28654766 |
2018 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
In 6 patients, a diagnosis of CD30+ lymphoproliferative disorder or Sézary syndrome was proposed or suspected histopathologically, and only the clinical context allowed the diagnosis of ELR with a peculiar presentation with atypical lymphocytes.
|
29107664 |
2018 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
CD30+ pseudolymphoma should be distinguished from malignant intravascular lymphoproliferative disorders.
|
29369392 |
2018 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
CD8-positive, CD30-positive cutaneous lymphoproliferative disorders constitute a rare subset of T-cell lymphoproliferative conditions, including variants of primary cutaneous anaplastic large cell lymphoma (ALCL), mycosis fungoides, lymphomatoid papulosis type D, cutaneous gamma-delta T-cell lymphoma and cutaneous peripheral T-cell lymphoma.
|
28497585 |
2017 |
|
Lymphoproliferative Disorders
|
0.100 |
AlteredExpression
|
group |
BEFREE |
CD30 Expression in Monomorphic Posttransplant Lymphoproliferative Disorder, Diffuse Large B-Cell Lymphoma Correlates With Greater Regulatory T-Cell Infiltration.
|
29126177 |
2017 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Hepatitis E virus-induced primary cutaneous CD30(+) T cell lymphoproliferative disorder.
|
28860025 |
2017 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Sinusoidal CD30+ diffuse large B-cell lymphoma can masquerade as anaplastic large cell lymphoma in pediatric posttransplant lymphoproliferative disorders.
|
28035754 |
2017 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
It represents a potential treatment for the CD30+ lymphoproliferative disorder lymphomatoid papulosis (LyP), which currently has no approved treatment.
|
28980004 |
2017 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Expression of CD30 in blastoid cutaneous infiltrates typically signifies a CD30 lymphoproliferative disorder, often requiring minimal immunohistochemical workup, if clinically consonant.
|
27893466 |
2017 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
A new era for cutaneous CD30-positive T-cell lymphoproliferative disorders.
|
27993440 |
2017 |
|
Lymphoproliferative Disorders
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Moreover, as CD30 antigen may be expressed by other malignancies, the potential therapeutic application is increasing, including at least diffuse large B-cell lymphoma, T-cell lymphomas other than ALCL and cutaneous lymphoproliferative disorders.
|
27592544 |
2017 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Diagnosis of PC-ALCL relies strongly on clinicopathologic correlation given the potential morphologic, clinical and molecular overlap with the other cutaneous CD30+ LPD, lymphomatoid papulosis, and more aggressive hematolymphoid neoplasms.
|
28342276 |
2017 |
|
Lymphoproliferative Disorders
|
0.100 |
AlteredExpression
|
group |
BEFREE |
CD30 is a tumor necrosis factor receptor (TNFR) family member whose expression is associated with Hodgkin's disease, anaplastic large cell lymphomas, and other T and B lymphoproliferative disorders in humans.
|
28993768 |
2017 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
The extent of CD30 positivity in SMPTCL needs to be defined further along with its association with other forms of CD30+ lymphoproliferative disease including its potential categorization as a form of endogenous CD30+ lymphoproliferative disease.
|
28965629 |
2017 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Mycosis fungoides (MF) is the most common primary cutaneous T-cell lymphoma (CTCL), followed by CD30+ lymphoproliferative disorders, including lymphomatoid papulosis (LyP) and primary cutaneous anaplastic large cell lymphoma (pcALCL).
|
26266670 |
2016 |
|
Lymphoproliferative Disorders
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We studied CD30 expression in types of aggressive B-cell lymphomas not previously studied, including Burkitt lymphoma, high-grade (grade III) follicular lymphoma, mixed grade III follicular lymphoma/diffuse large B-cell lymphoma (DLBCL), posttransplantation lymphoproliferative disease large B-cell lymphoma, and primary mediastinal large B-cell lymphoma.
|
27521276 |
2016 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
TOX staining was performed in MF, CD30(+) LPD, LPP as well as benign inflammatory dermatoses (BID) and normal skin (NS).
|
27345620 |
2016 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
CD30-positive primary cutaneous lymphoproliferative disorders include several entities with differing clinical presentation but overlapping histological features, including lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma (C-ALCL).
|
25131361 |
2015 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Once a diagnosis of lymphoma is established, it is important to exclude systemic anaplastic lymphoma kinase-negative ALCL involving the breast, primary cutaneous ALCL, and other CD30(+) lymphoproliferative disorders.
|
24878027 |
2014 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Therefore, we aimed to analyze the expression of 5-hmC in cutaneous CD30-positive lymphoproliferative disorders and compare it with a control group composed of reactive infectious and inflammatory disorders with CD30-positive cells.
|
25353265 |
2014 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Intralymphatic cutaneous anaplastic large cell lymphoma/lymphomatoid papulosis: expanding the spectrum of CD30-positive lymphoproliferative disorders.
|
24805854 |
2014 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
This is the first report of recurrent translocations involving TYK2, and it highlights the novel therapeutic opportunities in the treatment of CD30-positive LPDs with TYK2 translocations.
|
25349176 |
2014 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
SATB1 overexpression promotes malignant T-cell proliferation in cutaneous CD30+ lymphoproliferative disease by repressing p21.
|
24747435 |
2014 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Lymphomatoid papulosis (LyP) belongs to the spectrum of primary cutaneous CD30-positive lymphoproliferative disorders.
|
23026936 |
2013 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Primary cutaneous anaplastic large cell lymphoma is regarded as an ALK-negative variant confined to the skin and is part of the spectrum of primary cutaneous CD30-positive T-cell lymphoproliferative disorders.
|
22773605 |
2013 |